Fintel reports that on July 10, 2025, Wells Fargo downgraded their outlook for Verona Pharma plc - Depositary Receipt () ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh firm rides ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

U.S. appetite for U.K. companies is only intestifying in 2025; here, Law.com charts some of the highest profile deals in H1, ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

For the third time in four years, CNBC has ranked North Carolina as “America’s Top State for Business” in 2025.

US Foods Holding stock hit an all-time high Friday on a report that the firm was mulling an acquisition of Performance Food ...

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster. The first-in-class dual ...

The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo ...

Bank of America Securities analyst Jason Gerberry reiterated a Sell rating on ProKidney yesterday and set a price target of $1.00. The company’s shares opened today at $4.82. Take advantage of ...